PepVault
/ database / Nootropic Peptide

Dihexa

Also: PNB-0408

Orally active synaptogenic compound — promising preclinical cognition data.

Evidence
anecdotal
Legal status
research only
Half-life
Unclear in humans
Routes
oral
View on Limitless LifeAdd to compare
What it is

Dihexa was developed at Washington State University as a small, orally active angiotensin IV analog that drives new synapse formation via HGF/c-Met signaling. Preclinical cognitive enhancement in rats was dramatic.

Mechanism

Small angiotensin IV analog that activates HGF/c-Met to drive synaptogenesis.

Outcomes it's matched to
Safety

Theoretical concerns around uncontrolled growth (HGF signaling).

  • Active malignancy
  • Pregnancy
Legal context

Research use only. No human safety data.

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault